The present study showed for the first time that canagliflozin, an SGLT2 inhibitor, increased the average serum FABP4 concentration in patients with type 2 diabetes mellitus despite amelioration of glucose metabolism and reduction of adiposity (Fig 2A, Table 4). This evidence concerns the gene FABP4 and type 2 diabetes mellitus.